Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study.

被引：7
|
作者：
Cheng, Ke
Lv, Wan-Rui
Li, Xiaofen
Tian, Bole
Cao, Dan
机构：
[1] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Dept Abdominal Oncol, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16213
引用
收藏
页数：3
相关论文
共 50 条
  • [21] PanCO: Updated results of an open-label, single-arm pilot study of OncoSil P-32 microparticles in unresectable locally advanced pancreatic adenocarcinoma (LAPC) with gemcitabine plus nab-paclitaxel or FOLFIRINOX chemotherapy
    Ross, P.
    Hendlisz, A.
    Ajithkumar, T.
    Iwuji, C.
    Harris, M.
    Croagh, D.
    Aghmesheh, M.
    Nagrial, A.
    Nguyen, N.
    Nikfarjam, M.
    Wilson, N.
    Kenny, D.
    Turner, D.
    Wasan, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S232 - S232
  • [22] Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.
    Du, Juan
    Tong, Fan
    Sha, Hui-zi
    Sun, Yi
    Zhu, Yahui
    Qi, Liang
    Li, Xiaoqin
    Li, Wei
    Yang, Yan
    Li, Zeqing
    Xu, Caihua
    Ni, Jiayao
    Gu, Qing
    Zhang, Xing
    Zhu, Chan
    Wang, Xiaoxuan
    Liu, Baorui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] PanCO: An open-label, single-arm pilot study of Oncosil™ in patients with unresectable locally advanced pancreatic adenocarcinoma in combination with FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapies
    Harris, M.
    Croagh, D.
    Aghmesheh, M.
    Nagrial, A.
    Nguyen, N.
    Wasan, H.
    Ajithkumar, T.
    Kraszewski, A.
    Maher, T.
    Ross, P.
    ANNALS OF ONCOLOGY, 2018, 29 : 39 - 39
  • [24] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
    Fukahori, Masaru
    Miwa, Keisuke
    Murotani, Kenta
    Naito, Yoshiki
    Ushijima, Tomoyuki
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nagasu, Sachiko
    Suga, Hideya
    Kakuma, Tatsuyuki
    Okabe, Yoshinobu
    Torimura, Takuji
    MEDICINE, 2021, 100 (20) : E26052
  • [25] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
    P. G. Corrie
    W. Qian
    B. Basu
    J. W. Valle
    S. Falk
    C. lwuji
    H. Wasan
    D. Palmer
    M. Scott-Brown
    J. Wadsley
    S. Arif
    J. Bridgewater
    D. Propper
    R. Gillmore
    A. Gopinathan
    R. Skells
    P. Bundi
    R. Brais
    K. Dalchau
    L. Bax
    A. Chhabra
    A. Machin
    A. Dayim
    K. McAdam
    S. Cummins
    L. Wall
    R. Ellis
    A. Anthoney
    J. Evans
    Y. T. Ma
    C. Isherwood
    A. Neesse
    D. Tuveson
    D. I. Jodrell
    British Journal of Cancer, 2020, 122 : 1760 - 1768
  • [26] Gemcitabine plus Nab-paclitaxel as a second-line treatment for patients with advanced pancreatic cancer after FOLFIRINOX failure: a multicenter, single-arm, open-label, phase 2 trial
    Choi, Jin Ho
    Lee, Hee Seung
    Huh, Gunn
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 122 - 122
  • [27] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
    Corrie, P. G.
    Qian, W.
    Basu, B.
    Valle, J. W.
    Falk, S.
    Iwuji, C.
    Wasan, H.
    Palmer, D.
    Scott-Brown, M.
    Wadsley, J.
    Arif, S.
    Bridgewater, J.
    Propper, D.
    Gillmore, R.
    Gopinathan, A.
    Skells, R.
    Bundi, P.
    Brais, R.
    Dalchau, K.
    Bax, L.
    Chhabra, A.
    Machin, A.
    Dayim, A.
    McAdam, K.
    Cummins, S.
    Wall, L.
    Ellis, R.
    Anthoney, A.
    Evans, J.
    Ma, Y. T.
    Isherwood, C.
    Neesse, A.
    Tuveson, D.
    Jodrell, D., I
    BRITISH JOURNAL OF CANCER, 2020, 122 (12) : 1760 - 1768
  • [28] Durvalumab plus gemcitabine/cisplatin/nab-paclitaxel in resectable biliary tract cancer: A phase II, single-arm, open-label study (DurGAP)
    Li, Rentao
    Liu, Yang
    Liu, Yayue
    Fu, Linlin
    Qi, Qi
    Zhang, Xihao
    Cui, Yunlong
    Lu, Wei
    Li, Huikai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Updated results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase. clinical trial.
    Li, Ning
    Wu, Tao
    Hong, Yong-Gui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Wang, Junsheng
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 376 - 376
  • [30] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial
    Wang, J.
    Wu, T.
    Hong, Y-G.
    Luo, S-X.
    Li, N.
    Guo, Y-Z.
    Cheng, Y-F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1058 - S1058
12345